Prescription medicine
Dipyridamole First approved as Persantine
Dipyridamole (Persantine) is a prescription medicine with an FDA approval on record since 1961. FDA's NDC Directory lists it from 8 generic labelers, and pharmacies paid $0.236 per dipyridamole 75 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the dipyridamole FDA label on DailyMed (effective September 16, 2023, Zydus Pharmaceuticals USA Inc.); the NDA 12836 record on Drugs@FDA; every dipyridamole label on DailyMed.
Highlights of the record
FDA label of September 16, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageDipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
Forms and strengths
- 25 mg
- 50 mg
- 75 mg
- 5 mg/ml
Film-coated tablet; tablet; injection.
On the market
- Earliest approval on file
- December 6, 1961 Persantine, Boehringer Ingelheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 22 first September 29, 1980; 9 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 8 of which 8 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.236 per tablet Dipyridamole 75 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2016 0 Class I among all firms' recalls; latest October 6, 2016
- FAERS reports
- 3,743 through July 30, 2026
What is dipyridamole used for?
From the label: indications and usageDipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
FDA pharmacologic class: Platelet Aggregation Inhibitor.
Source: FDA drug label (Dipyridamole), Zydus Pharmaceuticals USA Inc., effective September 16, 2023 (SPL set 004bada0-dbf7-4a94-8792-6833d7eeda2b), via openFDA; the full label on DailyMed
Is there a generic for dipyridamole (Persantine)?
The FDA approved the first generic dipyridamole on September 29, 1980. 22 generic applications are approved; 9 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists dipyridamole from 8 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1961 earliest approval on file
- 1980 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for dipyridamole (Persantine)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.236 per Dipyridamole 75 mg tablet, down 34% from $0.358 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Dipyridamole 25 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Dipyridamole 25 mg tablet | Generic | $0.136 per tablet | $4.08 | -31% |
| Dipyridamole 50 mg tablet | Generic | $0.357 per tablet | $10.72 | +9% |
| Dipyridamole 75 mg tablet | Generic | $0.236 per tablet | $7.07 | -34% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has dipyridamole been recalled?
The FDA's Enforcement Report lists 1 recall naming dipyridamole since 2016: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| October 6, 2016 | Class II | Boehringer Ingelheim Pharmaceuticals, Inc. | Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the dipyridamole label say about other medicines?
The dipyridamole label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 9 other medicines name dipyridamole. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Adenosine | drug interactions | Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. |
| Regadenoson | drug interactions | Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. |
Other labels that name dipyridamole
Source: FDA drug label (Dipyridamole), Zydus Pharmaceuticals USA Inc., effective September 16, 2023 (SPL set 004bada0-dbf7-4a94-8792-6833d7eeda2b), via openFDA; the full label on DailyMed
What do FAERS reports show for dipyridamole?
The FDA Adverse Event Reporting System holds 3,743 reports that list dipyridamole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 461 are coded as a death and 1,931 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other platelet aggregation inhibitors
- the pharmacologic class, with prices and generics
- Dipyridamole side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other